Bambuterol is a long acting beta2-adrenoceptor agonist for the management of lung diseases associated with bronchospasm. It is a prodrug of terbutaline.
- Mechanism
- Curator reviewed
The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
- Primary indication
- For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.Curator reviewed · 4 structured indications
- Formula / weight
- C18H29N3O5 · 367.44 g/mol (avg)
Resolves to
ANZXOIAKUNOVQU-UHFFFAOYSA-NSMILESCN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Bambuterol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account